EIKEN CHEMICAL CO.,LTD. 4549
ζ „η ”εŒ–ε­¦ζ ͺ式会瀾 Β· Medical Devices Β· Prime
Governance Compliance: TSE Status: Disclosed English Reports Available
Similar β€Ί
Fact Sheet (PDF)
Eiken Chemical Co., Ltd. engages in the manufacture and sale of clinical diagnostics in Japan. It offers microbiological reagents for diagnosis of microorganism infection, such as mediums, antimicrobial susceptibility, and rapid test reagents; urinalysis test strips for occult blood, protein, and glucose; and fecal immunochemical tests reagents for screening of colorectal cancer. The company also provides immunological and serological reagents to detect and monitor infectious disease, rheumatism, inflammation, atrophic gastritis, and prostate specific antigens; and clinical chemistry tests to measure and analyze biological components in blood serum and urine. In addition, it sells reagents and devices of microbiological test for food poisoning bacteria and environmental inspection; and offers nucleic acid amplification method, as well as provides various types of automated analyzers. The company was formerly known as Nihon Eiyokagaku Co., Ltd. and changed its name to Eiken Chemical Co., Ltd. in 1969. Eiken Chemical Co., Ltd. was incorporated in 1939 and is headquartered in Tokyo, Japan.
Price
Β₯2,700
Market Cap
Β₯90.2B
Ent. Value
Β₯83.3B
Net Cash
Β₯6.9B
Shares Out.
33.4M
P / E
41.7Γ—
EV / EBIT
27.8Γ—
P / Book
2.09Γ—
P / NCAV
7.07Γ—
Div. Yield
1.96%
⬇ Excel
Metric FY 2024
EDINET β†— 		FY 2023
EDINET β†— 		FY 2022
EDINET β†— 		FY 2021
EDINET β†— 		FY 2020
EDINET β†—
Net Sales Β₯40.5B Β₯40.1B Β₯43.3B Β₯43.0B Β₯38.7B
Cost of Sales Β₯24.0B Β₯23.3B Β₯22.8B Β₯22.4B Β₯20.1B
Gross Profit Β₯16.5B Β₯16.7B Β₯20.5B Β₯20.6B Β₯18.5B
SG&A Β₯13.5B Β₯13.3B Β₯13.0B Β₯12.2B Β₯11.9B
Operating Income Β₯3.0B Β₯3.4B Β₯7.5B Β₯8.4B Β₯6.6B
Non-Operating Income Β₯235M Β₯284M Β₯154M Β₯164M Β₯220M
Dividend Income Β₯3M Β₯4M Β₯3M Β₯2M Β₯2M
Interest Income Β₯14M Β₯8M Β₯15M Β₯18M Β₯17M
Non-Operating Expenses Β₯36M Β₯93M Β₯42M Β₯43M Β₯24M
Interest Expense Β₯17M Β₯17M Β₯16M Β₯7M Β₯2M
Ordinary Income Β₯3.2B Β₯3.6B Β₯7.6B Β₯8.5B Β₯6.8B
Pre-tax Income Β₯3.0B Β₯3.5B Β₯7.6B Β₯8.5B Β₯6.9B
Income Taxes Β₯763M Β₯869M Β₯1.9B Β₯2.3B Β₯1.8B
Current Tax Β₯701M Β₯767M Β₯1.8B Β₯2.1B Β₯1.8B
Deferred Tax Β₯62M Β₯101M Β₯97M Β₯176M Β₯3M
Net Income (owners) Β₯2.2B Β₯2.6B Β₯5.7B Β₯6.2B Β₯5.0B
Comprehensive Income Β₯2.0B Β₯2.9B Β₯5.6B Β₯6.3B Β₯5.5B
EBITDA Β₯5.6B Β₯5.7B Β₯9.6B Β₯10.4B Β₯8.3B
EPS Β₯64.82 Β₯71.69 Β₯155.17 Β₯168.28 Β₯136.65
Shares Outstanding 33.4M 34.6M 37.0M 37.0M 36.9M
Shares Issued (total) 38.5M 40.0M 43.5M 43.5M 43.5M
Treasury Shares 5.1M 5.4M 6.5M 6.6M 6.6M